Core Points - Hemostemix Inc has announced a non-brokered private placement increasing gross proceeds to $3,000,000 due to oversubscriptions [1] - Each Unit in the placement is priced at $0.10 and includes one Common Share and one Warrant, with the Warrant exercisable at $0.15 for two years [2] - Certain directors of Hemostemix are participating in the Offering, which is classified as a related party transaction under MI 61-101 [3] Financial Details - The proceeds from the private placement will be used to repay CD1 at a 50% discount to face value ($1,250,000) and for general working capital [4] - The Company has a history of clinical studies, with seven studies involving 318 subjects, demonstrating the efficacy of its VesCell™ therapy [5] Company Overview - Hemostemix is focused on autologous stem cell therapy and has developed VesCell™ (ACP-01), which has shown significant clinical results in treating various cardiovascular conditions [5] - The Company has received recognition as a Technology Pioneer by the World Economic Forum and has published results in ten peer-reviewed publications [5]
Hemostemix Closing $3,000,000 Private Placement
Newsfile·2025-07-17 20:10